CAJ | 학술논문

老年急性髓性白血病(AML)患者的预后在最近30年间没有明显改善,老年患者的特点限制了其耐受强烈化疗的能力并且导致更高的早期死亡率.老年AML患者很大一部分有既往血液学疾病史,其白血病细胞有预后不良的遗传学异常,表达多药耐药基因(MDR1),这些特点导致对化疗耐药.近30年间研究、应用了许多方法.现对老年AML患者治疗研究进展作一综述.
노년급성수성백혈병(AML)환자적예후재최근30년간몰유명현개선,노년환자적특점한제료기내수강렬화료적능력병차도치경고적조기사망솔.노년AML환자흔대일부분유기왕혈액학질병사,기백혈병세포유예후불량적유전학이상,표체다약내약기인(MDR1),저사특점도치대화료내약.근30년간연구、응용료허다방법.현대노년AML환자치료연구진전작일종술.
The outcome of the elderly patients with acute myeloid leukemia (AML) has not improved in the last three decades. Their clinical features limit the ability to tolerate intensive cytotoxic chemotherapy and result in greater early mortality. The AML seen in elderly patients is also more likely to have greater resistance to therapy. Attempts to improve outcome have generally been unsuccessful But further manipulation of standard cytotoxic chemotherapy alone is unlikely to improve the outcome for the majority of patients with AML.